Oaktree Capital
SuperinvestorOaktree Capital Management LP
- SEC CIK
- 0000949509
- Manager
- Howard Marks
- Style
- Value
- Latest filing
- Aug 13, 2026
SRNE holding history
Sorrento Therapeutics, Inc. in every 13F filed by Oaktree Capital, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SRNE overviewAll 13F holders of SRNEFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −134,000−100.0% | Sold out | Holders |
| Q1 2023 | 134,000 | $48.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 134,000 | $118.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 134,000 | $210.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 134,000 | $269.0K | <0.1% | −16,000−10.7% | Reduced | Holders |
| Q1 2022 | 150,000 | $349.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 150,000 | $697.0K | <0.1% | +16,000+11.9% | Added | Holders |
| Q3 2021 | 134,000 | $1.02M | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2021 | 134,000 | $1.30M | <0.1% | −186,000−58.1% | Reduced | Holders |
| Q1 2021 | 320,000 | $2.65M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.